Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Por um escritor misterioso
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overvie
Spotlight on brexpiprazole and its potential in the treatment of schiz
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals
Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for #Alzheimers agitation. Will it find its way to #Parkinsons? Depends on if it makes motor symptoms significantly worse. It works on D2
PDF] Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
Brexpiprazole - Mechanism of Action and Clinical Application
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
ex99-01_img005.jpg
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
